The purpose of this multi-site study is to develop and evaluate a multi-phase implementation and sustainment strategy to support evidence-based practice use across different interventions for individuals with autism, settings, and ages.
*In partnership with UCLA, UC Davis, Rochester, Penn, Drexel, and Kansas
The aims of the current project are to: 1) Engage stakeholders to identify targets for ACT SMART redesign to optimize its fit for middle and high school providers who serve autistic adolescents; 2) Conduct prototyping and usability field testing of the redesigned ACT SMART and iteratively refine to ensure usability, feasibility, acceptability, and appropriateness for use in schools.
This application seeks to address gaps in our understanding of fetal alcohol spectrum disorder in adults (FASD) by evaluating protracted effects of prenatal alcohol exposure (PAE) on the brain. Individuals aged 30 and 60, who were diagnosed with FASD in childhood, and matched controls, who had previous structural MRI scans in their teens and twenties will be recruited to have another MRI session in which structural, DTI, and connectivity assessments will be conducted. Comparisons between these and earlier scans will provide insight into the changes in overall brain structure, white matter integrity, and function with age in subjects with alcohol exposure histories. We postulate that brain maturation following PAE follows an altered trajectory relative to normal developing controls.
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer’s disease.
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer’s disease.